Iradimed (IRMD) Projected to Release Earnings on Thursday

Iradimed (NASDAQ:IRMD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.43 per share and revenue of $19.33 million for the quarter. Iradimed has set its Q1 2025 guidance at 0.390-0.430 EPS and its FY 2025 guidance at 1.710-1.810 EPS.

Iradimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical equipment provider reported $0.40 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.05). The business had revenue of $19.39 million for the quarter, compared to analyst estimates of $19.09 million. Iradimed had a net margin of 26.26% and a return on equity of 24.12%. On average, analysts expect Iradimed to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Iradimed Trading Up 0.4 %

IRMD stock traded up $0.19 during trading on Friday, hitting $53.32. The company had a trading volume of 28,235 shares, compared to its average volume of 44,531. The business has a 50 day moving average of $52.62 and a 200 day moving average of $54.22. The firm has a market capitalization of $677.96 million, a price-to-earnings ratio of 35.55 and a beta of 0.82. Iradimed has a fifty-two week low of $40.55 and a fifty-two week high of $63.29.

Iradimed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 5th. Stockholders of record on Monday, February 24th were issued a $0.17 dividend. The ex-dividend date of this dividend was Monday, February 24th. This is a boost from Iradimed's previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 1.28%. Iradimed's dividend payout ratio (DPR) is 45.33%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. StockNews.com upgraded Iradimed from a "buy" rating to a "strong-buy" rating in a research report on Friday. Roth Mkm reiterated a "buy" rating and issued a $72.00 price target (up from $60.00) on shares of Iradimed in a research report on Friday, February 14th.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.